Sentinel Oncology wins Innovation in Drug Discovery Award
“Sentinel Oncology is delighted to be recognised by ERBI in receipt of this award for innovation in drug discovery“said Bob Boyle of Sentinel Oncology. “Our technology represents an exciting opportunity to develop new drugs that will offer improved treatment options for cancer patients”.
The company have progressed from the early start-up phase and now have a strong pipeline of discovery programmes, all of which are relevant to the treatment of difficult to cure cancers.
The ERBI BIOTECH Regional Awards 2008 were announced during ERBI’s Winter Ball on Saturday 29th November which was held at Duxford’s Imperial War Museum. The Innovation in Drug Discovery & Development Award 2008 recognises the contribution a company makes to the UK's dominant position in the development of innovative new medicines.
Sentinel Oncology was founded at the beginning of 2005 by Bob Boyle, Stuart Travers and Gavin Simpson. In March 2006 Sentinel received investment from the Cambridge University Challenge Fund. At the same time the company appointed Professor Ashok Venkitaraman, at the Department of Oncology based at the Hutchison/MRC research centre to the board of Sentinel Oncology as a non-Executive Director. During 2007 further funding was received from the Wellcome Trust as part of their "Seeding Drug Discovery" initiative.
Commenting on the award, Stuart Travers said: “Sentinel Oncology focuses on the development of drugs that exploit tumour hypoxia and DNA response pathways. This is a novel approach that we have successfully developed in collaboration with a world class advisory network. Our ultimate goal is the discovery of drugs for untreatable cancers and we are honoured to be recognised by ERBI for our efforts”.
